Working… Menu
Trial record 88 of 228 for:    yeast

Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome (ARMP-11)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02295176
Recruitment Status : Completed
First Posted : November 20, 2014
Last Update Posted : October 27, 2015
Information provided by (Responsible Party):

Brief Summary:

Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity in patients with MetS and increased LV mass.

168 patients will be enrolled in this randomized, double-blind, parallel-group, placebo-controlled trial and treated for 24 weeks.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Insulin-resistance Left Ventricular Hypertrophy Dietary Supplement: Armolipid Plus Dietary Supplement: Placebo Not Applicable

Detailed Description:

Metabolic syndrome (MetS) is a highly prevalent condition characterized by visceral obesity, abnormalities of glucidic and lipid metabolism, and increased risk for cardiovascular events. Such findings appear to be associated with a decrease in insulin sensitivity. Management of metabolic syndrome is currently aimed at treating individual components of the disease without addressing this underlying pathophysiologic mechanism; this translates into multidrug regimens, high costs and patient compliance issues.

A complication of hypertension is hypertrophy of the left ventricle (LV), which is closely related to the incidence of cardiovascular events whose regression results in a proportional reduction of the risk. But also other factors contribute as sex, age, race, genetics, diet and insulin resistance.

MetS is closely related to hypertrophy of the LV. Therefore it is possible that the treatment of MetS may be an effective strategy for the prevention of organ damage.

Armolipid Plus (an association of berberine 500mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg, coenzyme Q10 2mg,astaxanthin 0,5mg, folic acid 0,2mg) has been found to be effective at reducing blood cholesterol and triglycerides, and at improving endothelial function; subgroup analyses also suggested a benefit on glucose metabolism, myocardial mass and improved diastolic function in subjects with MetS and early organ damage.

Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity in patients with MetS and increased LV mass.

168 patients will be enrolled in this randomized, double-blind, parallel-group, placebo-controlled trial; active treatment will consist of Armolipid Plus (1 tbl qd).

Primary end point will be the reduction of the insulin resistance in patients with metabolic syndrome and increased LV mass.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 159 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Metabolic and Cardiovascular Effects of a Proprietary Nutraceutical Containing Berberine, Policosanols and Red Yeast in Subjects With Metabolic Syndrome
Study Start Date : April 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Armolipid Plus
Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.
Dietary Supplement: Armolipid Plus
Placebo Comparator: Placebo
1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks
Dietary Supplement: Placebo

Primary Outcome Measures :
  1. Primary outcome measure will be the reduction of the insulin/glucose ratio, both after overnight fast (HOMA index) [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. cardiac remodeling assessed by echocardiogram, lipid profile, subtypes of LDL, blood pressure, and high-sensitivity C-reactive protein. [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male and Female 18-70 aged, with diagnosis of metabolic syndrome, defined by the presence of waist circumference >102 cm (♂) or >88 cm(♀), and two or more of these criteria:

    • fasting blood glucose >100 mg
    • systolic blood pressure >135 or diastolic blood pressure >85 mmHg or patients in treatment with antihypertensive drugs
    • triglyceridemia >150 mg/dl
    • HDL cholesterolemia < 40 mg/dl(M), < 50 mg/dl(F).
  • left ventricular hypertrophy: left ventricular mass indexed to height >44 g/m2,7(♀)or >48 g/m2(♂).
  • antihypertensive and lipid-lowering therapy (if applicaple) stable for at least three months.
  • ability to understand and sign an informed consent form.

Exclusion Criteria:

  • pregnancy or lactation period
  • diabetes mellitus or pharmacological treatment for this condition
  • hepatic failure
  • creatininemia >2mg/dl
  • triglyceridemia >500mg/dl
  • severe obesity (BMI >35)
  • chronic renal failure with glomerular filtration rate <30ml/min
  • triglycerides >500mg/dl
  • left ventricular systolic dysfunction (LVEF <40%)
  • hypertrophic cardiomyopathy
  • valvular stenosis
  • previous myocardial infarction with acinesie
  • intermediate or severe cardiac valve disorders
  • intolerance to any components of Armolipid Plus
  • pacemaker generated arrhythmia
  • Inadequately controlled high blood pressure during therapy optimization (SBP >140mmHg or DBP >90mmHg)
  • patients with comorbidities are allowed (e.g. ischemic heart disease, dysthyroidism) but they have got to be in stable therapy for at least 3 months and they did not have major clinical events in the last three months;
  • heart failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02295176

Layout table for location information
Domenico Bonaduce
Naples, Italy, 80131
Ferruccio Galletti
Naples, Italy
Giuseppe Schillaci
Terni, Italy
Sponsors and Collaborators

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Rottapharm Identifier: NCT02295176     History of Changes
Other Study ID Numbers: ARMP-11
First Posted: November 20, 2014    Key Record Dates
Last Update Posted: October 27, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertrophy, Left Ventricular
Metabolic Syndrome
Insulin Resistance
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Pathological Conditions, Anatomical
Heart Diseases
Cardiovascular Diseases